These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 32707199)

  • 1. Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies.
    Hassan MB; Stern C; Flanagan EP; Pittock SJ; Kunchok A; Foster RC; Jitprapaikulsan J; Hodge DO; Bhatti MT; Chen JJ
    Am J Ophthalmol; 2020 Dec; 220():110-114. PubMed ID: 32707199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.
    Chen JJ; Tobin WO; Majed M; Jitprapaikulsan J; Fryer JP; Leavitt JA; Flanagan EP; McKeon A; Pittock SJ
    JAMA Ophthalmol; 2018 Apr; 136(4):419-422. PubMed ID: 29470571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
    Jitprapaikulsan J; Chen JJ; Flanagan EP; Tobin WO; Fryer JP; Weinshenker BG; McKeon A; Lennon VA; Leavitt JA; Tillema JM; Lucchinetti C; Keegan BM; Kantarci O; Khanna C; Jenkins SM; Spears GM; Sagan J; Pittock SJ
    Ophthalmology; 2018 Oct; 125(10):1628-1637. PubMed ID: 29716788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.
    Pache F; Zimmermann H; Mikolajczak J; Schumacher S; Lacheta A; Oertel FC; Bellmann-Strobl J; Jarius S; Wildemann B; Reindl M; Waldman A; Soelberg K; Asgari N; Ringelstein M; Aktas O; Gross N; Buttmann M; Ach T; Ruprecht K; Paul F; Brandt AU;
    J Neuroinflammation; 2016 Nov; 13(1):282. PubMed ID: 27802824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China.
    Zhao G; Chen Q; Huang Y; Li Z; Sun X; Lu P; Yan S; Wang M; Tian G
    J Neurol; 2018 Jan; 265(1):33-40. PubMed ID: 29101456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
    Ramanathan S; Prelog K; Barnes EH; Tantsis EM; Reddel SW; Henderson AP; Vucic S; Gorman MP; Benson LA; Alper G; Riney CJ; Barnett M; Parratt JD; Hardy TA; Leventer RJ; Merheb V; Nosadini M; Fung VS; Brilot F; Dale RC
    Mult Scler; 2016 Apr; 22(4):470-82. PubMed ID: 26163068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
    Chen JJ; Bhatti MT
    Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China.
    Song H; Zhou H; Yang M; Tan S; Wang J; Xu Q; Liu H; Wei S
    Br J Ophthalmol; 2019 Jun; 103(6):831-836. PubMed ID: 30049802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study.
    Stiebel-Kalish H; Lotan I; Brody J; Chodick G; Bialer O; Marignier R; Bach M; Hellmann MA
    PLoS One; 2017; 12(1):e0170847. PubMed ID: 28125740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis.
    Martinez-Hernandez E; Sepulveda M; Rostásy K; Höftberger R; Graus F; Harvey RJ; Saiz A; Dalmau J
    JAMA Neurol; 2015 Feb; 72(2):187-93. PubMed ID: 25506781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics of Pediatric Optic Neuritis With Myelin Oligodendrocyte Glycoprotein Seropositive: A Cohort Study.
    Chen Q; Zhao G; Huang Y; Li Z; Sun X; Lu P; San Y; Wang M; Tian G
    Pediatr Neurol; 2018 Jun; 83():42-49. PubMed ID: 29778487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.
    Chen JJ; Flanagan EP; Jitprapaikulsan J; López-Chiriboga ASS; Fryer JP; Leavitt JA; Weinshenker BG; McKeon A; Tillema JM; Lennon VA; Tobin WO; Keegan BM; Lucchinetti CF; Kantarci OH; McClelland CM; Lee MS; Bennett JL; Pelak VS; Chen Y; VanStavern G; Adesina OO; Eggenberger ER; Acierno MD; Wingerchuk DM; Brazis PW; Sagen J; Pittock SJ
    Am J Ophthalmol; 2018 Nov; 195():8-15. PubMed ID: 30055153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis.
    Liu H; Zhou H; Wang J; Sun M; Teng D; Song H; Xu Q; Wei S
    J Neurol Sci; 2019 Jan; 396():225-231. PubMed ID: 30522039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
    Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
    J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optic neuritis in the era of biomarkers.
    Chen JJ; Pittock SJ; Flanagan EP; Lennon VA; Bhatti MT
    Surv Ophthalmol; 2020; 65(1):12-17. PubMed ID: 31425702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan.
    Ishikawa H; Kezuka T; Shikishima K; Yamagami A; Hiraoka M; Chuman H; Nakamura M; Hoshi K; Goseki T; Mashimo K; Mimura O; Yoshitomi T; Tanaka K;
    Ophthalmology; 2019 Oct; 126(10):1385-1398. PubMed ID: 31196727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.